Death at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher complete remission at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in 100% increase in serum creatinine at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids may leads to higher adverse events ‐ temporary/permanent discontinuation or… compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
Adverse events ‐ infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ infection at 3 years compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ malignancy at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Periodontitis (probing pocket depth) · Adults, 16 years and older (dentate)
The review found no eligible studies for this question.
1 finding from 1 review
Gingivitis · Adults, 16 years and older (dentate)
It is very uncertain whether oral irrigation plus toothbrushing changes gingivitis (gingival index) compared with flossing plus toothbrushing (very low certainty).
2 findings from 1 review
Periodontitis (probing pocket depth) · Adults, 16 years and older (dentate)
1 finding from 1 review
Gingivitis · Adults, 16 years and older (dentate)
It is very uncertain whether oral irrigation plus toothbrushing changes gingivitis (gingival index) compared with toothbrushing alone (very low certainty).
2 findings from 1 review
Plaque · Adults, 16 years and older (dentate)
Oral irrigation plus toothbrushing showed no clear difference in plaque compared with toothbrushing alone (low certainty).
1 finding from 1 review
Side effects · Adults, 16 years and older (dentate)
1 finding from 1 review
Three studies reported that there were no adverse events, one reported one incidence of aphthous ulcer in irrigator group, one reported oral lacerations but found no difference between the interventions, and one did…
5 studies
GRADE not reported
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: participant‐rated good/excellent control of symptoms… compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: headache · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: adverse events ‐ headache Folluw‐up: 48 weeks to 72 weeks compared with placebo (high certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity in TLSSc and mTLSSd · people with moderate to severe chronic hand eczema
The review found no eligible studies for this question.
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review